FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Hosted on MSN10m
Non-Opioid Pain Medication Journavx Gets FDA Approval
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Hosted on MSN23m
FDA Approves Painkiller Aimed At Eliminating Opioid Addiction Risks
Federal officials have approved new pain medication Journavx, designed to offer short-term pain relief without the addiction and overdose risks associated with opioids like Vicodin and OxyContin. The ...
The San Joaquin Valley Sun24m
Painkiller designed without risk of addiction approved by FDA
The U.S. Food and Drug Administration (FDA) has approved a new pain pill called Journavx, designed to mitigate the risks of addiction and overdose associated with opioid medications like Vicodin and ...
aha.org39m
FDA approves first-in-class non-opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
FDA approved the first new kind of pain medication in 27 years. Here’s how it works
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Healio1h
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
Psychology Today1h
Treating Pain—Avoiding the Brain
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
FDA approves suzetrigine, the first new painkiller since 1998
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the agency since 1998.
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.